Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: Camrelizumab Sponsor:   Beijing Sanbo Brain Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials